The Medi-Vantage sweet spot is in minimally invasive interventional procedures.
A recent project was in Transcatheter Aortic Valve Repair (TAVR). Heart valve disease is the most common type of heart disease and is estimated to afflict > 1.5 M people in the US. TAVR, first used in humans in 2002, offers the benefit of non-invasive surgery with the effectiveness of total valve replacement for patients who have high surgical risk or are inoperable.
The transcatheter aortic valve replacement market has experienced substantial growth in recent years; US and EU combined revenue was estimated at $485 M in 2011 and was expected to surpass $830 M for 2012.
Medi-Vantage interventional expertise includes:
- Interventional Cardiology
- Interventional Radiology
- Structural Heart
- Stroke Treatment
- TAVR (Transcatheter Aortic Valve Repair)
How Can We Help You?
The Medi-Vantage team is here to drive growth and profitability for your company.